🇺🇸 FDA
Pipeline program

TKM-100802 for Injection

TKM-EBOV-002

Phase 1 small_molecule terminated

Quick answer

TKM-100802 for Injection for Ebola Virus Infection is a Phase 1 program (small_molecule) at Arbutus Biopharma Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
Arbutus Biopharma Corp
Indication
Ebola Virus Infection
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials